Vinay Minocha, MD
Hematology & Oncology · Miami, FLNPI 1720342371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Johnson & Johnson at 24.5% of the total.
Across 230 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Pfizer$791
- Seagen Inc.$309
- Merck$294
- E.r. Squibb & Sons, L.L.C.$282
- Eisai Inc.$261
- plus $2K from 26 others
Across 8 payments — averaging $13,380 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$96K
- Mirati Therapeutics, Inc.$11K
What the payments were for
- Food & beverage$4,97892%
- Education$4348%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 41 | $1,325 |
| Pfizer | 50 | $791 |
| Seagen Inc. | 7 | $309 |
| Merck | 14 | $294 |
| E.r. Squibb & Sons, L.L.C. | 13 | $282 |
| Eisai Inc. | 9 | $261 |
| Novartis | 11 | $225 |
| EMD Serono, Inc. | 7 | $222 |
| Array Biopharma Inc | 12 | $194 |
| Janssen Scientific Affairs, LLC | 4 | $187 |
| Bayer | 7 | $147 |
| Astellas Pharma US Inc | 6 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $130 |
| Lilly USA, LLC | 6 | $129 |
| Amgen | 6 | $103 |
| Daiichi Sankyo Inc. | 5 | $98 |
| Sanofi | 4 | $76 |
| Sobi, Inc | 3 | $75 |
| GE HealthCare | 1 | $50 |
| Caris MPI, Inc. | 2 | $48 |
| AstraZeneca | 2 | $47 |
| Foundation Medicine, Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $40 |
| Genentech USA, Inc. | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| AbbVie | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,412 in reported general payments places this provider in the 55th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 13 | $333,365 |
| ErleadaApalutamide | 21 | $306,098 |
| Abiraterone Acetate | 113 | $295,213 |
| XtandiEnzalutamide | 18 | $237,033 |
| VerzenioAbemaciclib | 15 | $220,955 |
| EliquisApixaban | 16 | $20,006 |
| Prochlorperazine Maleate | 33 | $858 |
| LoperamideLoperamide Hcl | 33 | $831 |
| Ondansetron Hcl | 30 | $819 |
| Prednisone | 69 | $379 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $242 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $164 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $162 |
| Tramadol Hcl | 19 | $155 |
| Gabapentin | 18 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $19 | $333,36513 claims |
| Johnson & JohnsonErleada | $1,325 | $306,09821 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $187 | $295,213113 claims |
| Astellas Pharma US IncXtandi | $141 | $237,03318 claims |
| Lilly USA, LLCVerzenio | $129 | $220,95515 claims |
| PfizerEliquis | $791 | $20,00616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.